FdaApplication
NDA 216540
Identifiers
- fda_app_no: NDA216540
Properties
| Property | Value |
|---|---|
| applicant_name | BRIDGEBIO PHARMA INC |
| application_type | NDA |
| approval_date | 2024-11-22 |
Revenue by product
ATTRUBY
| Period | Revenue |
|---|---|
| Q2 2026 | $222.4M |
| Q1 2026 | $180.6M |
| Q3 2025 | $108.1M |
| Q2 2025 | $71.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ATTRUBY | ACORAMIDIS HYDROCHLORIDE | EQ 356MG BASE | TABLET;ORAL |
1 product